A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene

Molecular and Cellular Probes

Volumn 13, Issue 4, 1999, Pages 321-323

  Gadzicki, D ^a   Muller Vahl K ^a   Stuhrmann, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anandamide; Central cannabinoid receptor; CNR1 gene; Gilles de la Tourette syndrome; Restriction fragment length polymorphism

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR; CANNABIS;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GERMANY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MOLECULAR CLONING; MOLECULAR GENETICS; OBSESSION; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

CANNABIS;

EID: 0344562864     PISSN: 08908508     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcpr.1999.0249     Document Type: Article

References (14)

1. Hoehe M. R., Caenazzo L., Martinez M. M., Hsieh W. T., Modi W. S., Gershon E. S., Bonner T. I. Genetic and physical mapping of the human cannabinoid receptor gene chromosome 6q14-q15. New Biology. 3:1991;880-885.
2. Gerard C. M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal. 279:1991;129-134.
3. Howlett A. C., Flemming R. M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology. 26:1984;532-538.
4. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Science, USA. 89:1992;3825-3829.
5. Consroe P., Sandyk R., Snider S. R. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience. 30:1986;277-282.
6. Sieradzan K. A., Fox S. H., Dick J., Brotchie J. M. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with ideopathic Parkinsons disease (PD). Movement disorders. 13 , (Suppl. 2):1998;29.
7. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple scleroris. European Neurology. 38:1997;44-48.
8. Hemming M., Yellowlees P. M. Effective treatment of Tourettes syndrome with marijuana. Journal of Psychopharmacology. 7:1993;289-291.
9. Müller-Vahl K. R., Kolbe H., Schneider U., Emrich H. M. Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette-Syndrom. Acta Psychiatrica Scandinayica. 98:1998;502-506.
10. Westlake T. M., Howlett A. C., Bonner T. I., Matsuda L. A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimers brains. Neuroscience. 63:1994;637-652.
11. Caenazzo L., Hoehe M. R., Hsieh W.-T., Berrettini W. H., Bonner T. I., Gershon E. S. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucleic Acids Research. 19:1991;4798.
12. Commings D. E., Muhleman D., Gade R., Johnson P., Verde R., Saucier G., Macmurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Molecular Psychiatry. 2:1997;161-168.
13. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics. 5:1989;874-879.
14. Haliassos A., Chomel J., Tesson A. Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Research. 17:1989;3606.